Milestone Pharmaceuticals Inc. (MIST) stock
Close on Nov 11, 2026Market cap $82.44MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $82.44M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.53
- Dividend yield
- –
- Free cash flow yield
- -74.77%
Fundamentals
- Net income
- -$84.01M
- EPS, diluted
- -$0.75
- Free cash flow
- -$61.65M
Trading
- Next earnings
- Nov 11, 2026 (estimated, before the open)
- Previous close
- $0.66
- Open
- $0.69
- Day's range
- $0.65 – $0.71
- Volume
- 6,450,689
- Average volume (20 days)
- 1,224,924
- Beta (5 years)
- 1.40
- 52-week range
- $0.63 – $3.06
- RSI (14 days)
- 40.7
- Volatility (1 year)
- 77.0%
- Relative volume
- 4.95×
- WACC
- 11.9%
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | MIST | S&P 500 | Difference | MIST per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -13.4% | -2.4% | −11.0 pts | ||
| 3 months | -47.9% | -1.2% | −46.7 pts | ||
| Year to date | -67.2% | +12.3% | −79.5 pts | ||
| 1 year | -65.3% | +12.4% | −77.8 pts | ||
| 3 years | -77.2% | +78.8% | −156.1 pts | -38.9% | +21.4% |
| 5 years | -88.2% | +75.2% | −163.3 pts | -34.8% | +11.9% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Milestone Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- Results
- Results
- News
- News
About Milestone Pharmaceuticals
Pharmaceutical Preparations
Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel cardiovascular medicines. Its lead commercial product is CARDAMYST (etripamil) nasal spray, a self-administered, rapid-onset calcium channel blocker designed to convert acute symptomatic attacks of paroxysmal supraventricular tachycardia (PSVT) into normal sinus rhythm. In addition to commercializing CARDAMYST, the company develops etripamil to manage acute ventricular rates in patients suffering from atrial fibrillation with rapid ventricular rate (AFib-RVR). Its target customers comprise healthcare providers—predominantly clinical cardiologists, interventional cardiologists, electrophysiologists, and select primary care physicians—who treat adult patients with these episodic cardiac arrhythmias, with products supplied via third-party logistics to drug wholesalers and retail pharmacies.
Company profile, executives and historyMilestone Pharmaceuticals stock: common questions
What is Milestone Pharmaceuticals's stock price?
MIST closed at $0.66 on Nov 11, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $0.63 and $3.06.
What is Milestone Pharmaceuticals's market cap?
Milestone Pharmaceuticals was worth $82.44M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is MIST's P/E ratio?
Milestone Pharmaceuticals lost money over fiscal 2025 (diluted EPS -$0.75), so it has no meaningful P/E ratio.
Does Milestone Pharmaceuticals pay a dividend?
No. Milestone Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Milestone Pharmaceuticals report earnings next?
Milestone Pharmaceuticals is expected to report Q3 FY2026 results on Nov 11, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has MIST stock performed over the past year?
Including dividends, MIST returned -65.3% over the past year, against +12.4% for the S&P 500.
How many MIST shares are sold short?
20M shares were sold short at the latest FINRA report, 16.13% of the float, or 24.8 days of average trading volume.
Who are Milestone Pharmaceuticals's competitors?
Companies most similar to Milestone Pharmaceuticals by business, industry and size include KNSA, ASBP, LXRX, TLPH, CYTK.
See a number that looks wrong?